<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04090580</url>
  </required_header>
  <id_info>
    <org_study_id>3089</org_study_id>
    <nct_id>NCT04090580</nct_id>
  </id_info>
  <brief_title>Impact on Glycemic Variability After Treatment With Dapagliflozin on Type 2 Diabetes Patients</brief_title>
  <official_title>Impact on Glycaemic Variability, Oxidative Stress and Inflammatory Disease Biomarkers After Treatment With Dapagliflozin as Dual Therapy With Metformin on Mexican Type 2 Diabetes Patients. A Randomized, Open-label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AztraZeneca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glycemic variability is refered as swings in glucemic concentration throughout the day,
      including preprandial and postprandial glucose, and it has been proposed that could be
      determinant in the development in microvascular complications of type 2 diabetes (Brownlee
      and Hirsch 2006) SGLT2 inhibitors (SGLT2i) are a novel group of medications for treating type
      2 diabetes patients but their effect on glucose variability, and oxidative stress has not
      been determined as a primary endpoint in clinical trials of type 2 diabetes mellitus
      patients. The aim of this study is to compare the effect of SGLT2 inhibition on glucose
      variability, oxidative stress and inflammatory disease biomarkers (VCAM-1) on new onset type
      2 DM patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to compare the effect of SGLT2 inhibition on glucose variability,
      oxidative stress and inflammatory disease biomarkers (VCAM-1) on new onset type 2 DM
      patients. Methods: The investigators will include 36 patients with type 2 diabetes diagnosis
      with an Hba1c ≥ 7.5% and ≤ 9%, with BMI &gt; 25 and &lt;45 kg/m2, drug-naïve subjects. Subjects
      enrolled will be randomized 1:1 to either receive a daily dosage of dapagliflozin 10 mg and
      2000 mg metformin for 12 weeks (n=18) or 2000 mg metformin (n=18). Patients who do not
      tolerate metformin at 2000mg dose will be downtitrated to 1500 mg daily. In case patients do
      not tolerate 1500 mg daily, they will be excluded. Patients who do not achieve glycaemic
      control, another antihyperglycaemic drug can be used.

      Both groups will be monitored for 7 days using either iPro™ CGM system (Medtronic,
      Northridge, CA) or Dexcom G6 CGM (Dexcom Inc, San Diego, CA), or other available in Mexico.
      Basal continuous glucose monitoring will start at week 1 (first visit), and removed at day 7
      and final continuous glucose monitoring will start at week 11 and removed 7 days after (final
      visit).

      The main variables of interest are going to be in order of importance the delta of change
      (before and after study entry) of: 1.- glycaemic variability, 2.- change in Hba1c. 3.- change
      in oxidative stress status, 4. change in VCAM-1, 5.- change in weight, 6.- Blood pressure and
      7.- waist circumference; before and after SGLT2i. The expected results are: compared to
      standard treatment, dapagliflozin arm will have lower glycaemic variability, higher reduction
      in Hba1c, lower oxidative stress, lower inflammsatory biomarker levels, and lower blood
      pressure
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2019</start_date>
  <completion_date type="Anticipated">August 27, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 27, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of dapagliflozin in glycemic variability</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients from both groups (dapagliflozin + metformin and metformin) will be monitored for 7 days using either iPro™ CGM system (Medtronic, Northridge, CA) or Dexcom G6 CGM (Dexcom Inc, San Diego, CA). Basal continuous glucose monitoring will start at week 1 (first visit), and removed at day 7 and final continuous glucose monitoring will start at week 11 and removed 7 days after (final visit) comparing glycemic variability between them. Mean difference of glycaemic variability (MAGE) calculated in mmol/L.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of dapagliflozin in insulin level concentration</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean difference of insulin serum concentrations represented in μU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of dapagliflozin in Hba1c</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean difference of HbA1c represented in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of dapagliflozin on patients weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean difference of weight represented in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of dapagliflozin in blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean difference of systolic and diastolic blood pressure represented in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of dapagliflozin in waist circumference</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean difference waist measured in centimeters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Daily dosage of dapagliflozin and metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects enrolled will be randomized 1:1 to either receive a daily dosage of 10 mg dapagliflozin and 2000 mg metformin for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily dosage of metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects enrolled will be randomized 1:1 to either receive a daily dosage of 2000 mg metformin for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Continuous glucose monitoring</intervention_name>
    <description>Subjects enrolled will be randomized 1:1 to either receive a daily dosage of dapagliflozin 10 mg and 2000 mg metformin for 12 weeks (n=18) or 2000 mg metformin (n=18). Patients who do not tolerate metformin at 2000mg dose will be downtitrated to 1500 mg daily. In case patients do not tolerate 1500 mg daily, they will be excluded.
Both groups will be monitored for 7 days using either iPro™ CGM system (Medtronic, Northridge, CA) or Dexcom G6 CGM (Dexcom Inc, San Diego, CA). Basal continuous glucose monitoring will start at week 1 (first visit), and removed at day 7 and final continuous glucose monitoring will start at week 11 and removed 7 days after (final visit).</description>
    <arm_group_label>Daily dosage of dapagliflozin and metformin</arm_group_label>
    <arm_group_label>Daily dosage of metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects &gt; 18-77 years-old

          -  Both Male and female

          -  Hba1c ≥ 7.5 % and ≤9%

          -  BMI &gt; 25 and &lt;45 kg/m2

          -  Type 2 diabetes diagnosis, drug-naïve

        Exclusion Criteria:

          -  Hba1c &gt; 9%

          -  Creatinine clearance CKD-EPI: &lt; 60 mL/min

          -  LADA or Type 1 diabetes

          -  Gestational diabetes

          -  Clinically significant disease like: hepatic, hematological, oncological, psychiatric
             or rheumatic disease.

          -  Symptoms of marked uncontrolled diabetes: (marked poliuria or polidipsia + 10% weight
             loss prior the last 3 months enrollement)

          -  Known hypersensitivity to dapagliflozin or any of the excipients of the product

          -  eGFR persistently &lt;45 mL/min/1.73 m2

          -  Unstable or rapidly progressing renal disease

          -  Patients with severe hepatic impairment (Child-Pugh class C)

          -  Any major CV event/Vascular Disease within 3 months prior to signing the consent at
             enrolment, as assessed by the investigator

          -  For women only - currently pregnant (confirmed with positive pregnancy test) or
             breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>77 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Angel Gomez Samano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miguel Angel Gomez Samano, MD</last_name>
    <phone>55 54870900</phone>
    <phone_ext>2405</phone_ext>
    <email>gsamano83@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán ''INCMNSZ''</name>
      <address>
        <city>Ciudad de mexico</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Ángel Gómez Sámano, MD</last_name>
      <phone>55 54870900</phone>
      <phone_ext>2405</phone_ext>
      <email>miguelangelgomezsamano@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Miguel Angel Gómez Sámano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Cuévas Ramos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Javier Gómez Pérez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Horacio Correa Carranza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alejandra Domínguez Sánchez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 11, 2019</study_first_submitted>
  <study_first_submitted_qc>September 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>Miguel Ángel Gómez Sámano</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>dapagliflozin</keyword>
  <keyword>glycemic variability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT04090580/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT04090580/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

